Linda Robinson, MD
Family Practice · Coats, NCNPI 1699753970
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $654 and has fallen 96.7% since, to $21 in 2025. Among family practice clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$357
- Boehringer Ingelheim$155
- Takeda Pharmaceuticals U.S.A., Inc.$152
- Pfizer$147
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$115
- Esperion Therapeutics, Inc.$102
- plus $831 from 19 others
What the payments were for
- Food & beverage$1,860100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $357 |
| Boehringer Ingelheim | 8 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $152 |
| Pfizer | 7 | $147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $115 |
| Esperion Therapeutics, Inc. | 5 | $102 |
| Merck | 5 | $94 |
| AbbVie | 6 | $91 |
| Lilly USA, LLC | 5 | $82 |
| Ultragenyx Pharmaceutical Inc. | 3 | $70 |
| AstraZeneca | 5 | $68 |
| Amgen(2 entities) | 3 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Novartis | 2 | $53 |
| Scilex Pharmaceuticals Inc. | 2 | $47 |
| Abbott | 2 | $47 |
| Mylan Specialty L.p. | 2 | $31 |
| Eisai Inc. | 1 | $24 |
| Gilead | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,860 in reported general payments places this provider in the 95th percentile of 458 family practice providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 22 | $65,848 |
| EliquisApixaban | 88 | $54,426 |
| JardianceEmpagliflozin | 21 | $21,254 |
| TrulicityDulaglutide | 20 | $18,659 |
| OzempicSemaglutide | 18 | $17,534 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,853 |
| JanuviaSitagliptin Phosphate | 23 | $12,261 |
| XareltoRivaroxaban | 17 | $8,924 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,429 |
| TradjentaLinagliptin | 12 | $6,342 |
| FarxigaDapagliflozin Propanediol | 11 | $5,912 |
| Fentanyl | 25 | $4,273 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $2,722 |
| SynthroidLevothyroxine Sodium | 34 | $2,546 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 68 | $2,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $147 | $54,42688 claims |
| Boehringer IngelheimJardiance, Tradjenta | $155 | $27,59633 claims |
| Lilly USA, LLCTrulicity | $82 | $18,65920 claims |
| Novo NordiskOzempic | $357 | $17,53418 claims |
| MerckJanuvia | $94 | $12,26123 claims |
| AstraZenecaFarxiga | $68 | $5,91211 claims |
| AbbVieSynthroid | $91 | $2,54634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 458 family practice providers in North Carolina.
Other family practice in Coats
- Samina IsmailRaleigh$2K
- Kelly BullardFayetteville$1K
- Nazik Al-HashimiDurham$288
- Uma PendemChapel Hill$222
- Hannah SmithMount Pleasant$196
- Ravin JayatissaLumberton$146
- Madahari HenryElizabeth City$125
- Amanda AustinNags Head$122
- Mary HampeCarrboro$114
- Elena BeidlerDurham$72
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.